Short-Term Androgen Deprivation Therapy and 18 F-flotufolastat PSMA PET/CT Imaging for Prostate Cancer Staging: A Pilot Study
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Introduction
This pilot study evaluates the impact of short-term androgen deprivation therapy (ADT) on the findings on 18 F-flotufolastat PSMA PET/CT scan when used for staging prostate cancer prior to a robot-assisted radical prostatectomy (RARP) and bilateral pelvic lymphadenectomy (PLND).
Methods
Ten patients with unfavorable intermediate, high, or very-high risk prostate cancer were assigned to one of two cohorts, A and B (n=5 each). Baseline serum prostate-specific antigen (PSA) and testosterone were measured, followed by an 18 F-flotufolastat PSMA PET/CT. All patients then underwent either 3 weeks (Cohort A) or 6 weeks (Cohort B) of relugolix therapy. A second PSMA PET/CT was performed immediately upon ADT completion. Quantitative and qualitative changes in PSMA PET/CT findings were analyzed.
Results
All patients reached castrate levels of testosterone (<20 ng/dL) within 3 weeks of the initiation of ADT. Only 1 patient (10%) exhibited a 16.1% increase in the maximum standardized uptake value (SUVmax) of the primary intraprostatic lesion. No new clinically significant findings were detected on the post-ADT PSMA PET/CT compared to pre-ADT scans, and no pre-existing findings were obscured post-ADT. No serious adverse events related to ADT were reported.
Discussion
Short-term ADT (3 and 6 weeks) did not alter PSMA PET/CT findings in a manner that would impact surgical planning or management.
